Figure 2.
Model of the clonal progression process that occurs between the initial (de novo) and relapse presentation in AML patients. At diagnosis, this patient has an oligoclonal disease characterized by four different subclones, each present at a specific proportion in the tumor cell population and with a specific mutational profile. Chemotherapy used to induce the patient into remission decreases clonal heterogeneity but a single subclone persists, acquires new mutations, and again proliferates in the bone marrow as a relapse-specific subclone.